search

Active clinical trials for "Osteoporosis, Postmenopausal"

Results 71-80 of 295

Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density

Low Bone Mineral DensityPostmenopausal Osteoporosis

The primary objective was to determine the effect of treatment with romosozumab versus placebo at month 12 on the percent change from baseline in bone mineral density (BMD) at the lumbar spine in postmenopausal women with low bone density.

Completed36 enrollment criteria

Study of Transitioning From Alendronate to Denosumab

Postmenopausal Osteoporosis

The study will evaluate the efficacy and safety of transitioning postmenopausal women on current alendronate therapy to denosumab. Endpoints studied will include bone mineral density, bone turnover markers and bone histology in a subset of subjects.

Completed9 enrollment criteria

Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal...

Osteoporosis Postmenopausal

To confirm the non-inferiority of 75 mg risedronate tablets taken on 2 consecutive days per month as compared to 5 mg risedronate tablets taken daily in increasing bone mass in lumbar spine in postmenopausal women with osteoporosis. To confirm the efficacy of 75 mg risedronate tablets taken on 2 consecutive days per month in postmenopausal women with osteoporosis in increasing bone mass in proximal femur, femoral neck and femoral trochanter and decreasing bone resorption. To confirm general safety of 75 mg risedronate tablets taken on 2 consecutive days per month as compared to 5 mg risedronate taken daily.

Completed7 enrollment criteria

A Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmenopausal Women With...

OsteoporosisPostmenopausal

The purpose of this study and 12 month extension is to evaluate the effects of two investigational drugs on osteoporosis in postmenopausal women.

Completed2 enrollment criteria

A Study of Monthly Risedronate for Osteoporosis

Postmenopausal Osteoporosis

The purpose of this trial is to study the efficacy of a single-dose monthly dosing regimen as compared to the standard daily dosing regimen of risedronate 5 mg daily.

Completed8 enrollment criteria

Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women...

Postmenopausal Osteoporosis

To determine the effect and safety of menatetrenone on treatment of postmenopausal osteoporosis comparing with alfacalcidol.

Completed17 enrollment criteria

Influence of Alfacalcidol on Falls in Osteopenic/Osteoporotic Postmenopausal Women (ALFA Study)...

OsteoporosisPostmenopausal2 more

The purpose of this study is to evaluate the effect of alfacalcidol 1 µg daily on the number of fallers in postmenopausal, alendronate-treated, osteopenic or osteoporotic women. primary outcome = number of fallers (patients with at least one locomotor fall incl.mixed falls)

Completed15 enrollment criteria

DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate)...

Post Menopausal Osteoporosis

This study will assess the efficacy and safety of intravenous administration of Bonviva regimens in women with post-menopausal osteoporosis, compared to oral daily administration. Patients will also receive daily supplementation with vitamin D and calcium. The anticipated time of study treatment is 2+ years, and the target sample size is 500+ individuals.

Completed8 enrollment criteria

Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis

OsteoporosisPostmenopausal

The purpose of this study is to compare treatment with both teriparatide and raloxifene with teriparatide alone. The study will evaluate any side effects that may be associated with the two drugs and may help to determine whether teriparatide and raloxifene together can help patients with osteoporosis more than teriparatide alone.

Completed10 enrollment criteria

Antiresorptive Effect of Treatment With Risedronate and Vitamin D in Postmenopausal Patients

Postmenopausal OsteoporosisHypovitaminosis D1 more

Osteoporosis is defined as a systemic disease of bone mineralization, characterized by a decrease in bone mineral density that causes bone fragility and increases the risk of fractures during menopause. Recently, a high prevalence of hypovitaminosis D has been found worldwide, which could trigger a state of secondary hyperparathyroidism that can worsen the state of postmenopausal patients with osteoporosis. An open-label, clinical trial was conducted in Mexican women with postmenopausal osteopenia-osteoporosis to determine the efficacy of the combined treatment with risedronate and high-dose vitamin D in improving bone mineral density, hyperparathyroidism, and hypovitaminosis D.

Completed8 enrollment criteria
1...789...30

Need Help? Contact our team!


We'll reach out to this number within 24 hrs